Therapeutic Targets in Inflammatory Bowel Disease: Current and Future

[1]  S. Rose-John,et al.  The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. , 2015, Current opinion in immunology.

[2]  R. Maciuca,et al.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.

[3]  C. Klein,et al.  Very Early-onset Inflammatory Bowel Disease: Gaining Insight Through Focused Discovery , 2015, Gastroenterology & hepatology.

[4]  H. Kettenberger,et al.  Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2015, Proceedings of the National Academy of Sciences.

[5]  S. Vermeire,et al.  901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study , 2015 .

[6]  S. Vermeire,et al.  445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis , 2015 .

[7]  A. Amiot,et al.  829 Long-Term Outcomes in a Cohort of Patients With Acute Severe Ulcerative Colitis Refractory to Intravenous Steroids Treated With Cyclosporine or Infliximab , 2015 .

[8]  D. Clemmons,et al.  Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. , 2015, Gastroenterology.

[9]  S. Hanauer,et al.  Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial , 2015, Inflammatory bowel diseases.

[10]  Maria Fichera,et al.  Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. , 2015, The New England journal of medicine.

[11]  Graham M Lord,et al.  Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease , 2015, Gut.

[12]  M. Fujimiya,et al.  Stem cell therapy for inflammatory bowel disease , 2015, Journal of Gastroenterology.

[13]  W. Reinisch,et al.  Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study , 2015, Gut.

[14]  A. Kaser,et al.  Role of endoplasmic reticulum stress and autophagy as interlinking pathways in the pathogenesis of inflammatory bowel disease , 2015, Current opinion in gastroenterology.

[15]  M. Vandervoort,et al.  A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity , 2015, Alimentary pharmacology & therapeutics.

[16]  Dan Knights,et al.  Complex host genetics influence the microbiome in inflammatory bowel disease , 2014, Genome Medicine.

[17]  M. Murad,et al.  Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[18]  L. Peyrin-Biroulet,et al.  Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study , 2014, Gut.

[19]  C. Yu,et al.  TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans. , 2014, Journal of Crohn's & colitis.

[20]  S. Bombardieri,et al.  A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate. , 2014, The Israel Medical Association journal : IMAJ.

[21]  K. Taylor,et al.  Association of NOD2 and IL23R with Inflammatory Bowel Disease in Puerto Rico , 2014, PloS one.

[22]  W. Sandborn,et al.  A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  C. Bain,et al.  Macrophages in intestinal homeostasis and inflammation , 2014, Immunological reviews.

[24]  Sarah Spiegel,et al.  Sphingolipid metabolites in inflammatory disease , 2014, Nature.

[25]  S. Targan,et al.  Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis , 2014, Mucosal Immunology.

[26]  Xin Chen,et al.  Th17 cells and Tregs: unlikely allies , 2014, Journal of leukocyte biology.

[27]  A. Kostic,et al.  The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.

[28]  J. Däbritz.  Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[29]  Se Jin Song,et al.  The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.

[30]  Désirée van der Heijde,et al.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[31]  R. Cabezón,et al.  Therapeutic Potential of Tolerogenic Dendritic Cells in IBD: From Animal Models to Clinical Application , 2013, Clinical & developmental immunology.

[32]  A. Segal,et al.  What Is Wrong with Granulocytes in Inflammatory Bowel Diseases? , 2013, Digestive Diseases.

[33]  W. Garrett,et al.  The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis , 2013, Science.

[34]  Yusun Jung,et al.  Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations , 2013, Gut.

[35]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[36]  S. Targan,et al.  Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn’s Disease , 2013, Inflammatory bowel diseases.

[37]  S. Targan,et al.  SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS. , 2013, European journal of microbiology & immunology.

[38]  Yusuke Nakamura,et al.  Association Study of 71 European Crohn's Disease Susceptibility Loci in a Japanese Population , 2013, Inflammatory bowel diseases.

[39]  B. Hartmann,et al.  Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. , 2013, The Journal of allergy and clinical immunology.

[40]  D. M. van der Heijde,et al.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial , 2013, Annals of the rheumatic diseases.

[41]  M. Silverberg,et al.  IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[42]  J. González,et al.  Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project , 2012, Gut.

[43]  L. Biancone,et al.  A phase 1 open‐label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease , 2012, Alimentary pharmacology & therapeutics.

[44]  A. Foussat,et al.  Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. , 2012, Gastroenterology.

[45]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[46]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[47]  J. Puchalka,et al.  Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. , 2012, Gastroenterology.

[48]  D. Mould,et al.  Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study , 2012, Inflammatory bowel diseases.

[49]  J. Macdonald,et al.  Sargramostim (GM‐CSF) for Induction of Remission in Crohn's Disease: A Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Systematic Review of Randomized Trials , 2012, Inflammatory bowel diseases.

[50]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[51]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[52]  S. Targan,et al.  Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. , 2012, The American journal of pathology.

[53]  L. Honigberg,et al.  Functional Studies on the IBD Susceptibility Gene IL23R Implicate Reduced Receptor Function in the Protective Genetic Variant R381Q , 2011, PloS one.

[54]  T. Mizushima,et al.  Therapeutic Effects of Novel Sphingosine-1-Phosphate Receptor Agonist W-061 in Murine DSS Colitis , 2011, PloS one.

[55]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[56]  H. Ogata,et al.  Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. , 2011, Gastroenterology.

[57]  F. Rieux-Laucat,et al.  Defective IL10 Signaling Defining a Subgroup of Patients With Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.

[58]  P. Rutgeerts,et al.  Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment , 2011, The American Journal of Gastroenterology.

[59]  Ke Wu,et al.  IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer , 2011, The Journal of Immunology.

[60]  Steven W. Martin,et al.  The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study , 2011, Gut.

[61]  K. Honda,et al.  Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.

[62]  S. Targan,et al.  Constitutive TL1A (TNFSF15) Expression on Lymphoid or Myeloid Cells Leads to Mild Intestinal Inflammation and Fibrosis , 2011, PloS one.

[63]  P. Vandamme,et al.  Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives , 2011, Gut.

[64]  A. Testori,et al.  Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. , 2010, Blood.

[65]  B. Psaty,et al.  Genetic predictors of medically refractory ulcerative colitis , 2010, Inflammatory bowel diseases.

[66]  N. Sebire,et al.  Infant colitis—it's in the genes , 2010, The Lancet.

[67]  F. Powrie,et al.  Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells , 2010, Immunity.

[68]  D. McKay,et al.  In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. , 2010, Gastroenterology.

[69]  J. Myśliwska,et al.  First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. , 2009, Clinical immunology.

[70]  G. Corazza,et al.  Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease , 2009, Gut.

[71]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[72]  Joseph T. Glessner,et al.  Genome wide association (GWA) predictors of anti‐TNF&agr; therapeutic responsiveness in pediatric inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[73]  N. Pullen,et al.  Pharmacological characterization of PF‐00547659, an anti‐human MAdCAM monoclonal antibody , 2009, British journal of pharmacology.

[74]  T. Mcclanahan,et al.  The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.

[75]  J. Hugot,et al.  TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort , 2009, The American Journal of Gastroenterology.

[76]  Y. Hannun,et al.  A role for sphingosine kinase 1 in dextran sulfate sodium‐induced colitis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[77]  T. Okanoue,et al.  Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. , 2008, Biochemical and biophysical research communications.

[78]  A. Cohen,et al.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[79]  S. Snapper,et al.  Regulatory T cells in inflammatory bowel disease , 2008, Current opinion in gastroenterology.

[80]  W. Strober,et al.  THE ROLE OF IL-13 AND NK T CELLS IN EXPERIMENTAL AND HUMAN ULCERATIVE COLITIS , 2008, Mucosal Immunology.

[81]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[82]  T. Hibi,et al.  IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease , 2008, Gut.

[83]  T. Nishida,et al.  A Novel Sphingosine 1-Phosphate Receptor Agonist, 2-Amino-2-propanediol Hydrochloride (KRP-203), Regulates Chronic Colitis in Interleukin-10 Gene-Deficient Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.

[84]  Javier Martín,et al.  Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[85]  Iwona Wrobel,et al.  IL‐23 receptor (IL‐23R) gene protects against pediatric Crohn's disease , 2007, Inflammatory bowel diseases.

[86]  P. Deloukas,et al.  IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease , 2007, Gastroenterology.

[87]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[88]  M. Marinaro,et al.  Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. , 2006, Gastroenterology.

[89]  J. Wehkamp,et al.  Paneth cells and the innate immune response , 2006, Current opinion in gastroenterology.

[90]  O. Inatomi,et al.  The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. , 2006, Oncology reports.

[91]  Erik Remaut,et al.  A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[92]  J. Ragoussis,et al.  Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. , 2005, Human molecular genetics.

[93]  G. Federici,et al.  Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. , 2005, Gastroenterology.

[94]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[95]  J. Korzenik,et al.  Sargramostim for active Crohn's disease. , 2005, The New England journal of medicine.

[96]  T. Macdonald,et al.  Immunity, Inflammation, and Allergy in the Gut , 2005, Science.

[97]  J. Korzenik,et al.  An open‐labelled study of granulocyte colony‐stimulating factor in the treatment of active Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[98]  S. V. van Deventer,et al.  A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.

[99]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[100]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[101]  B. Malissen,et al.  Selective Generation of Gut Tropic T Cells in Gut-associated Lymphoid Tissue (GALT) , 2003, The Journal of experimental medicine.

[102]  Jean Paul Remon,et al.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.

[103]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[104]  K. Asadullah,et al.  Interleukin-10 Therapy—Review of a New Approach , 2003, Pharmacological Reviews.

[105]  Y. Tabata,et al.  Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. , 2003, Journal of gastroenterology.

[106]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[107]  J. Korzenik,et al.  Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor , 2002, The Lancet.

[108]  A. Buchman,et al.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease , 2002, Gut.

[109]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[110]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[111]  E. Hahn,et al.  Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. , 2001, Gastroenterology.

[112]  S. Targan,et al.  ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. , 2001, Gastroenterology.

[113]  S. Targan,et al.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics , 2000, Gut.

[114]  W. Strober,et al.  Treatment of Experimental (Trinitrobenzene Sulfonic Acid) Colitis by Intranasal Administration of Transforming Growth Factor (Tgf)-β1 Plasmid , 2000, The Journal of Experimental Medicine.

[115]  J. Korzenik,et al.  Is Crohn's Disease an Immunodeficiency? , 2000, Digestive Diseases and Sciences.

[116]  C. Elia,et al.  Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease , 1999, Gut.

[117]  H. Okamura,et al.  Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. , 1998, Journal of immunology.

[118]  J. Panés,et al.  Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. , 1998, Gastroenterology.

[119]  K. Sullivan,et al.  Course of Crohn's disease after allogeneic marrow transplantation. , 1998, Gastroenterology.

[120]  B. Ludviksson,et al.  Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation , 1997 .

[121]  R. Coffman,et al.  A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells , 1996, The Journal of experimental medicine.

[122]  J. Fell,et al.  The distribution of dividing T cells throughout the intestinal wall in inflammatory bowel disease (IBD) , 1996, Clinical and experimental immunology.

[123]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[124]  R. Macdermott,et al.  Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .

[125]  J. Schölmerich,et al.  Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. , 1992, Gastroenterology.

[126]  S. Targan,et al.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. , 1990, The Journal of allergy and clinical immunology.

[127]  R. Okamoto,et al.  Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease , 2015, Journal of Gastroenterology.

[128]  R. Herrmann,et al.  A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[129]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[130]  C. Mackay,et al.  Diet, gut microbiota and immune responses , 2010, Nature Immunology.

[131]  B. Becher,et al.  RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. , 2009, Gastroenterology.

[132]  A. Andoh,et al.  Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. , 2004, Clinical immunology.

[133]  H. Tilg,et al.  Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. , 2002, Gut.

[134]  P. Rutgeerts,et al.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. , 1999, Gastroenterology.